New Type 2 Diabetes Drugs and Their Cardiovascular Effects – MM1703
Cardiovascular disease is the leading cause of death, morbidity and hospitalisation in people with type 2
diabetes. Several new classes of antidiabetic agents can improve various cardiovascular risk factors, including
weight, blood pressure and lipid profile, in addition to lowering blood glucose levels. Cardiovascular outcome
studies to date support the safety of three dipeptidyl peptidase-4 (DPP-4) inhibitors, one glucagon-like
peptide-1 (GLP-1) receptor agonist and one sodiumāglucose cotransporter-2 (SGLT-2) inhibitor in people with
type 2 diabetes. Specific cardiovascular benefits of DPP-4 inhibitors and GLP-1 receptor agonists over standard
diabetes therapy have not yet been demonstrated.
Modern Medicine – March 2017
